Fisogatinib Active Not Recruiting Phase 1 Trials for Hepatocellular Carcinoma Treatment

IndicationsStatusPurposePhase
Active Not RecruitingTreatment1
clinicaltrials.gov IdentifierTitleDrugs
NCT02508467A Phase 1 Study of Fisogatinib (BLU-554) in Patients With Hepatocellular Carcinoma